HIV IN MOTHERS AND INFANTS--IMMUNITY AND EARLY DIAGNOSIS

我们建议评估与母婴HIV相关的母体因素 在海地和美国的妇女中传播。 我们将确定数量， 形式的潜伏和积极复制艾滋病毒，并确定关系 母亲对艾滋病毒的免疫反应以及 母婴传播 定量聚合酶链反应- 将开发酶免疫测定法（PCR-EIA）来定量基因组mRNA， 和单、双剪接的mRNA来确定HIV基因的形式， 孕妇外周血和脐带血中的物质。 我们有 确定了21名受感染的海地成年人的基因序列， 确定了我们人群的共有序列。 肽从 将进行主要中和结构域（PND）以确定 针对除PND以外的表位的抗体的贡献 总的中和活性。 此外，我们将测量ADCC 母体血清的能力，病毒特异性细胞毒性T淋巴细胞（CTL）， 以及CD 4和CD 8阳性细胞的水平，以确定 免疫应答与母体病毒载量有关， 母婴传播 为了确定8周以下感染艾滋病毒的婴儿，我们将评估 用于DNA和RNA、抗HIV伊加和p24抗原血症的新型PCR检测 在酸水解后，HIV诱导T细胞增殖，并且特异性 出生时、1至2月龄和3至6月龄时的CTL应答。 婴儿这些反应的时间将被用来估计 婴儿在出生前和出生时感染的比例。 这些调查将利用储存的标本， 250多名艾滋病毒血清反应阳性的母亲， 感染的婴儿，以及两项正在进行的队列研究， 血清反应阳性的妇女所生的婴儿

We propose to assess maternal factors associated with maternal-infant HIV transmission in Haitian and U.S. women. We will determine the quantity and form of latent and actively replicating HIV and determine the relationship with the maternal immune response to HIV and the probability of maternal-infant transmission. Quantitative Polymerase chain reaction - Enzyme immunoassay (PCR-EIA) will be developed to quantify genomic mRNA, and singly and double spliced mRNA to determine the form of HIV genetic material in maternal peripheral blood and umbilical cord blood. We have determined the genetic sequence from 21 infected Haitian adults and determined the consensus sequence for our population. Peptides from the principle neutralizing domain (PND) will be made to determine the contribution of antibodies against epitopes other than those from the PND to overall neutralizing activity. Furthermore, we will measure the ADCC capacity of maternal sera, viral specific cytotoxic T-lymphocytes (CTL), and the level of CD4 and CD8 positive cells to determine if the level of immune responsiveness is associated with maternal viral load or maternal-infant transmission. To identify HIV infected infants under 8 weeks of age we will evaluate novel PCR assays for DNA and RNA, anti-HIV IgA, and p24 antigenemia following acid hydrolysis HIV induced T-cell proliferation, and specific CTL responses at birth, 1 to 2 months of age and at 3 to 6 months of age. The timing of these responses in infants will be used to estimate what proportion of infants were infected before and at the time of birth. These investigations will take advantage of stored specimens available from more than 250 HIV seropositive mothers of uninfected infants, 50 mothers of infected infants, and two ongoing cohort studies that enroll more than 150 infants born to seropositive women a year.